Updated analysis of the inducible T-cell co-stimulatory receptor (ICOS) agonist, GSK3359609 (GSK609), combination with pembrolizumab (PE) in patients (pts) with anti-PD-1/L1 treatment-naïve head and neck squamous cell carcinoma (HNSCC).

Eric Angevin,Stefanie L. Groenland,Annette M. Lim,Juan Martin-Liberal,Victor Moreno,José Manuel Trigo,Christophe Le Tourneau,Matthen Mathew,Daniel C. Cho,Aaron Richard Hansen,D. Vicente,Michele Maio,Antoine Italiano,Jessica Ruth Bauman,Michael Jon Chisamore,Helen Zhou,Catherine E. Ellis,Marc S. Ballas,Axel Hoos,Danny Rischin

Updated analysis of the inducible T-cell co-stimulatory receptor (ICOS) agonist, GSK3359609 (GSK609), combination with pembrolizumab (PE) in patients (pts) with anti-PD-1/L1 treatment-naïve head and neck squamous cell carcinoma (HNSCC).

2020

6517Background: INDUCE-1 (NCT02723955) is a first-in-human study investigating GSK609, an IgG4 ICOS agonist non-T-cell depleting antibody, as monotherapy and combination therapy with anti-cancer ag...

Keywords:

Receptor
anti pd 1
therapy naive
Agonist
in patient
Head and neck squamous-cell carcinoma
Pathology
Pembrolizumab
T cell
Medicine
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations